136 related articles for article (PubMed ID: 25298583)
1. Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals.
Garg M; Singhal T; Sharma H
Indian J Pharmacol; 2014; 46(5):527-30. PubMed ID: 25298583
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats.
Chennuru A; Saleem MT
Biomed Res Int; 2013; 2013():934239. PubMed ID: 24228260
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats.
Koti BC; Vishwanathswamy AH; Wagawade J; Thippeswamy AH
Indian J Exp Biol; 2009 Jan; 47(1):41-6. PubMed ID: 19317350
[TBL] [Abstract][Full Text] [Related]
4. Investigation on protective effect of Terminalia bellirica (Roxb.) against drugs induced cardiotoxicity in wistar albino rats.
Chaudhary R; Singh R; Verma R; Kumar P; Kumar N; Singh L; Kumar S S
J Ethnopharmacol; 2020 Oct; 261():113080. PubMed ID: 32534117
[TBL] [Abstract][Full Text] [Related]
5. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
Shaker O; Sourour DA
J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
[TBL] [Abstract][Full Text] [Related]
6. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
Cai C; Lothstein L; Morrison RR; Hofmann PA
J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
[TBL] [Abstract][Full Text] [Related]
7. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
Rigatos SK; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(1A):129-34. PubMed ID: 12017274
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of Talinum paniculatum (Jacq.) Gaertn. in doxorubicin-induced cardiotoxicity in hypertensive rats.
Souto CGRG; Lorençone BR; Marques AAM; Palozi RAC; Romão PVM; Guarnier LP; Tirloni CAS; Dos Santos AC; Souza RIC; Zago PMJJ; Lívero FADR; Lourenço ELB; Silva DB; Gasparotto Junior A
J Ethnopharmacol; 2021 Dec; 281():114568. PubMed ID: 34461188
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy.
Sharma H; Pathan RA; Kumar V; Javed S; Bhandari U
Int J Cardiol; 2011 Jul; 150(2):193-200. PubMed ID: 20452068
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats.
Rashikh A; Abul Kalam Najmi ; Akhtar M; Mahmood D; Pillai KK; Ahmad SJ
Hum Exp Toxicol; 2011 Feb; 30(2):102-9. PubMed ID: 20418268
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of whole fruit extract of pomegranate on doxorubicin-induced toxicity in rat.
Hassanpour Fard M; Ghule AE; Bodhankar SL; Dikshit M
Pharm Biol; 2011 Apr; 49(4):377-82. PubMed ID: 21391840
[TBL] [Abstract][Full Text] [Related]
12. Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats.
Abu-Elsaad NM; Abd Elhameed AG; El-Karef A; Ibrahim TM
J Med Food; 2015 Sep; 18(9):950-9. PubMed ID: 25590792
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy.
Schwebe M; Ameling S; Hammer E; Monzel JV; Bonitz K; Budde S; Schult K; Oswald S; Scheuch E; Grube M; Poesch A; Budde T; Ewert R; Schroeder HW; Kroemer HK; Bien-Möller S
Biochem Pharmacol; 2015 Mar; 94(2):109-29. PubMed ID: 25660617
[TBL] [Abstract][Full Text] [Related]
14. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.
Chen X; Chen Y; Bi Y; Fu N; Shan C; Wang S; Aslam S; Wang PW; Xu J
Cardiovasc Drugs Ther; 2007 Oct; 21(5):367-74. PubMed ID: 17924179
[TBL] [Abstract][Full Text] [Related]
15. Sheng-mai-san reduces adriamycin-induced cardiomyopathy in rats.
You JS; Huang HF; Chang YL; Lee YS
Am J Chin Med; 2006; 34(2):295-305. PubMed ID: 16552840
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
Matsui H; Morishima I; Numaguchi Y; Toki Y; Okumura K; Hayakawa T
Life Sci; 1999; 65(12):1265-74. PubMed ID: 10503942
[TBL] [Abstract][Full Text] [Related]
17. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Santos DL; Moreno AJ; Leino RL; Froberg MK; Wallace KB
Toxicol Appl Pharmacol; 2002 Dec; 185(3):218-27. PubMed ID: 12498738
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane protects the heart from doxorubicin-induced toxicity.
Singh P; Sharma R; McElhanon K; Allen CD; Megyesi JK; Beneš H; Singh SP
Free Radic Biol Med; 2015 Sep; 86():90-101. PubMed ID: 26025579
[TBL] [Abstract][Full Text] [Related]
19. The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin.
Alimoradi H; Barzegar-Fallah A; Hassanzadeh G; Mohammadi-Rick S; Asadi F; Delfan B; Abbasi A; Dehpour AR
Cardiovasc Toxicol; 2012 Dec; 12(4):318-25. PubMed ID: 22744232
[TBL] [Abstract][Full Text] [Related]
20. Heart rate dynamics in doxorubicin-induced cardiomyopathy.
Lončar-Turukalo T; Vasić M; Tasić T; Mijatović G; Glumac S; Bajić D; Japunžić-Žigon N
Physiol Meas; 2015 Apr; 36(4):727-39. PubMed ID: 25798626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
